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 1 
Abstract 2 
Context and objective: Growth hormone insensitivity with immune dysfunction caused by signal transducer 3 
and activator of transcription 5B (STAT5B) mutations is an autosomal recessive condition. Heterozygous 4 
mutations in other genes involved in growth regulation were previously associated with a mild height 5 
reduction. Our objective was to assess for the first time the phenotype of heterozygous STAT5B mutations.  6 
Methods: We genotyped and performed clinical and laboratorial evaluations in 52 relatives of 2 previously 7 
described Brazilian brothers with homozygous STAT5B c.424_427del mutation (21 heterozygous). 8 
Additionally, we obtained height data and genotype from 1,104 adult control individuals from the same 9 
region in Brazil and identified 5 additional families harboring the same mutation (18 individuals, 11 10 
heterozygous). Furthermore, we gathered the available height data from first-degree relatives of patients with 11 
homozygous STAT5B mutations (17 individuals from 7 families). Data from heterozygous individuals and 12 
non-carriers were compared. 13 
Results: Individuals carrying heterozygous STAT5B c.424_427del mutation were 0.6 SDS shorter than their 14 
non-carrier relatives (p= 0.009). Heterozygous subjects also had significantly lower SDS for serum 15 
concentrations of IGF-1 (p=0.028) and IGFBP-3 (p=0.02) than their non-carrier relatives. The 17 16 
heterozygous first-degree relatives of patients carrying homozygous STAT5B mutations had an average 17 
height SDS of -1.4 ± 0.8 when compared with population-matched controls (p < 0.001).  18 
Conclusions: STAT5B mutations in heterozygous state have a significant negative impact on height 19 
(approximately 3.9 cm). This effect is milder than the effect seen in the homozygous state, with height 20 
usually within the normal range. Our results support the hypothesis that heterozygosity of rare pathogenic 21 
variants contributes to normal height heritability. 22 
23 




Previous studies have demonstrated that while homozygous mutations in genes involved in growth 4 
regulation are causal of severe syndromic short stature, heterozygosity of the same variants can be associated 5 
with a milder height reduction 1-4. For instance, in the growth hormone (GH) - insulin-like growth factor 1 6 
(IGF-1) axis, heterozygous carriers of mutations in acid-labile subunit gene (IGFALS) 
3
 and IGF1 gene 
1
 7 
were shown to be significantly shorter than non-carriers, although generally still within the normal height 8 
range. These data support the concept that rare mono-allelic variants with moderate effects on phenotype can 9 
be associated with height variability 
5
 and, as such, can be an etiology for non-syndromic short stature 
6, 7
.  10 
Signal transducer and activator of transcription 5B (STAT5B) is a key mediator of GH signaling, as 11 
well as of other signaling pathways, including those of prolactin and interleukin 2 (IL2) 
8
. Since 2003, ten 12 
patients have been reported harboring seven different homozygous STAT5B mutations 
9-16
. These rare 13 
homozygous mutations in STAT5B cause growth hormone insensitivity (GHI) and manifestations of immune 14 
dysregulation, such as increased susceptibility for opportunistic infections, lymphoid interstitial pneumonia 15 
and eczema. GHI syndrome, classically associated with homozygous mutations in the growth hormone 16 
receptor gene (GHR), is characterized by severe postnatal growth failure, normal to elevated GH levels and 17 
low serum concentrations of ALS, IGF1 and insulin-like growth factor binding protein 3 (IGFBP-3). Unlike 18 
most GHI patients carrying defects in GHR, however, serum concentrations of growth hormone binding 19 
protein (GHBP), the proteolytically-cleaved extracellular domain of GHR, were normal and prolactin levels 20 
were increased in patients carrying homozygous STAT5B mutations (reviewed in 
8
). 21 
To date, STAT5B deficiency is considered an autosomal recessive condition. The impact of 22 
heterozygous STAT5B mutations on growth and the GH-IGF axis, however, has not been carefully evaluated, 23 
due in part to the rarity of described cases and families. To address this issue, we evaluated a large 24 
community, in which multiple members carry a previously described STAT5B frameshift mutation 15. By 25 
comparing their data with data from other families harboring other mutations in STAT5B, we provide 26 
evidence that heterozygous STAT5B mutations can influence stature. 27 
 28 
29 
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 1 
Subjects and methods 2 
 3 
Subjects 4 
We evaluated 52 relatives of two Brazilian brothers with characterized GHI due to homozygous 5 
STAT5B c.424_427del mutation. Furthermore, an active search was done to investigate the prevalence of this 6 
mutation in the region where the index cases were born, identifying five unrelated heterozygous individuals 7 
among 1,104 evaluated adult control subjects. Relatives of these five individuals were subsequently 8 
evaluated, totaling 18 subjects. Height data gathered from the remaining 1,099 adult control individuals 9 
(non-carriers of STAT5B c.424_427del mutation) in the same region were used to assess the local population 10 
height.  11 
Additionally, we gathered the available height data from first-degree heterozygous relatives of 12 
previously reported patients with homozygous STAT5B mutations. We also included in this group two 13 
recently diagnosed individuals heterozygous for STAT5B c.424_427del mutation, who lost two children with 14 
the same phenotype seen in patients with homozygous STAT5B mutations. In total, height data from 17 first-15 
degree relatives from 7 families were analyzed. 16 
These studies were approved by the local ethics committees, and the patients or guardians gave their 17 
written informed consent.  18 
 19 
Genotyping in families with STAT5B c.424_427del mutation 20 
Genomic DNA was isolated from peripheral blood leukocytes using standard techniques. Genotyping 21 
for STAT5B c.424_427del mutation was done by fragment analysis technique. The primers were designed to 22 
amplify the region around this mutation (primer sequences and amplification protocols are available upon 23 
request). Genotyping was performed after the clinical evaluation.  24 
 25 
Clinical and laboratory assessment in families with STAT5B c.424_427del mutation 26 
Individuals from families with STAT5B c.424-427del mutation were evaluated by an investigator 27 
blinded for STAT5B genotype. They were questioned about pneumopathies, eczema and other immune 28 
dysfunctions. Height and weight were assessed in all individuals. Total blood count, fasting glucose and 29 
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insulin, immunoglobulins G, A and E, basal GH, IGF-1, IGFBP-3 and prolactin were tested in 91% of the 1 
evaluated individuals. Serum GH, IGF-1, IGFBP-3, prolactin and immunoglobulin E were measured through 2 
chemiluminescence assays and immunoglobulins A and G through turbidimetry. IGF-1 and IGFBP-3 were 3 




Whole-exome sequencing  6 
Whole-exome sequencing of genomic DNA, obtained from the peripheral blood of one individual 7 
heterozygous for STAT5B c.424_427del mutation and with pneumopathy of unknown etiology, was 8 
performed with Illumina's Nextera Exome Enrichment kits (Illumina, San Diego, CA) for library preparation 9 
and exome capture, and the Illumina HiSeq sequencer. Alignments and variant annotation were made as 10 
previouly described 18. 11 
 12 
Statistical methods 13 
Because the patients came from many ethnic groups, height data were expressed as SDS for the 14 
appropriate country/ethnic group. The effect of one mutant allele vs. wild type was determined in the whole 15 
group. 16 
Groups were compared by unpaired t-test or ANOVA followed by Tukey test for numerical variables 17 
with normal distribution. Numerical variables without parametric distribution were analyzed by Mann-18 
Whitney Rank Sum Test or Kruskal-Wallis ANOVA on Ranks. Categorical data were compared between 19 
groups through chi-square test or Fisher’s exact test as appropriate. Statistical significance was assumed for p 20 
< 0.05. Statistical analysis were made with SigmaStat 3.5 (Systat Software Inc. Chicago, USA) and MedCalc 21 




Families harboring STAT5B c.424_427del mutation 26 
The largest Brazilian family consisted of two patients with homozygous STAT5B c.424_427del 27 
mutation, 21 heterozygous carriers (including their non-consanguineous parents) and 31 non-carrier relatives 28 
(Supplemental Figure 1). The other five families identified consisted of eleven heterozygous carriers and 29 
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seven non-carrier relatives. When polymorphic markers around this mutation were studied, the same 1 
haplotype was found in these six families, which was consistent with the presence of a founder effect (data 2 
not shown) 19. Consequently, we analyzed all individuals from the six families together (Table 1). 3 
In total, we analyzed data from 32 heterozygous carriers of STAT5B c.424_427del mutation (17 males) 4 
and 38 non-carrier family members (12 males). Unrelated spouses were not included. One heterozygous 5 
carrier was excluded from the height analysis because of severe short stature (height SDS -3.5) of unknown 6 
cause. Among the seventy evaluated individuals (aged 32.7 ± 18.5 years old), sixteen were children (7 7 
heterozygous for STAT5B mutation).  8 
Non-carrier subjects in these families had a similar height SDS to individuals from the local 9 
population (height SDS -0.2 ± 1.0 vs. -0.4 ± 0.8 respectively, p = 0.63). Heterozygous STAT5B c.424_427del 10 
individuals were significantly shorter (height SDS -0.8 ± 0.9) than their non-carrier relatives (height SDS 11 
difference of -0.6, p = 0.009, confidence interval 95% -1.1 to -0.2), although all were within the normal 12 
height range (Table 1). When the analysis was done excluding the children, the same results were obtained 13 
(height SDS -0.8 ± 0.9 vs. -0.2 ± 1.0 for heterozygous and non-carrier relatives respectively, p = 0.02, Figure 14 
1). Furthermore, heterozygous carriers had significantly lower IGF-1 and IGFBP-3 SDS than their non-15 
carrier relatives (Table 1). Other parameters, such as basal GH and prolactin concentrations, were not 16 
different between these groups. 17 
Present or past history of dermopathies was reported in 9 out of 32 individuals heterozygous for 18 
STAT5B c.424_427del mutation and in 1 out of 38 individuals who were non-carriers (p = 0.004). We 19 
clinically diagnosed eczema in four carriers. No differences in total blood count and immunoglobulin levels 20 
between carriers and non-carriers were observed (Table 1).  21 
One cousin of the probands, who was heterozygous for STAT5B c.424_427del mutation, presented 22 
with a moderate to severe restrictive pneumopathy of unknown etiology. Her disease was milder than the 23 
pneumopathy observed in patients homozygous for STAT5B mutations, since she was in her thirties and still 24 
not oxygen-dependent. Exome sequencing excluded other STAT5B mutations and mutations in genes 25 
normally associated with pneumopathies (data not shown). A lung biopsy of this patient showed areas of 26 
interstitial thickening near respiratory bronchioles, inflammatory interstitial infiltrate with lymphocytes, 27 
plasmocytes and histiocytes and mild interstitial fibrosis, which is compatible with lymphoid interstitial 28 
pneumonia. Her father, an obligatory heterozygous carrier for the same mutation, died of respiratory failure 29 
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secondary to an uninvestigated chronic pneumopathy, but he had confounding factors such as smoking and 1 
working as a miner. 2 
 3 
First-degree relatives of index cases carrying STAT5B mutations  4 
Height data were obtained in seventeen first-degree relatives of ten patients homozygous for STAT5B 5 
mutations (Table 2). Two Argentinian patients were adopted soon after birth and, consequently, data from 6 
their biological relatives were not available. Parents were consanguineous in four families and not 7 
consanguineous in three families. All these relatives were heterozygous for STAT5B mutations with an 8 




In adequate health and nutritional conditions, genetic variation is the main determinant of stature, 13 
accounting for approximately 80% of height variability 20. Recent genome-wide association studies (GWAS) 14 
identified 697 variants in 423 loci that, together, accounted for only one-fifth of adult height heritability 
21
. 15 
The individual effect of single nucleotide polymorphisms (SNPs) found in these studies, furthermore, is very 16 
small (less than 0.5 cm) 22. The inability of GWAS to explain all height heritability, despite the increasing 17 
number of evaluated individuals, suggests that numerous rare variants with large to moderate effect have a 18 
role in height variability 23. However, it is difficult to evaluate the importance of rare variants in height 19 
variability through the current available methods, since each private allele is restricted to a few families or 20 
small populations. 21 
In the present study, the analysis of a large family with many heterozygous carriers of the STAT5B 22 
c.424_427del mutation showed that these individuals are significantly shorter than their non-carrier relatives 23 
and local population controls (mean height SDS difference of 0.6). Assuming that the mean SD for adult 24 
height distribution is 6.5cm, the mean height loss seen in these individuals can be estimated at 3.9 cm, which 25 
is a much larger individual effect than the 0.5 cm attributed to SNPs identified in GWAS. The significant 26 
reduction in IGF-1 SDS and IGFBP-3 SDS seen with STAT5B c.424_427del heterozygous carriers, 27 
furthermore, suggests that a decreased responsiveness to GH action could explain, at least in part, the 28 
observed height reduction.  29 
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Moreover, the analysis of the available height data from carriers of the different STAT5B mutations 1 
also displayed a significant reduction in height when compared to their population controls, and was 2 
equivalent to a height decrease of 9.1 cm, an even greater difference than that observed for carriers of 3 
STAT5B c.424_427del mutation. This difference could be due to the relatively smaller number of first-degree 4 
relatives available for study, and/or to variable effects on height dependent on the individual STAT5B 5 
mutation itself. For the STAT5B c.424_427del mutation, the lack of expression of the mutant protein in 6 
reconstitution experiments (Hwa V, unpublished data) suggests that partial haploinsufficiency could explain 7 
the modest height reduction seen in heterozygous carriers. No dominant-negative STAT5B mutations have 8 
been reported to date, although, interestingly, a heterozygous STAT5B p.Gln177Pro variant was recently 9 
described in two GHI patients with severe short stature but no immunological dysfunction 
24
. 10 
Heterozygous mutations in other genes along the GH-IGF1 axis similarly show larger individual 11 
effects on height than SNPs, supporting our finding. For example, in a family carrying IGF1 p.V44M 12 
mutation, individuals heterozygous for this mutation were 0.6 SDS shorter (equivalent to 3.9 cm) than their 13 
non-carrier relatives 1. Moreover, heterozygous carriers of IGFALS mutations were 0.9 SDS shorter 14 
(equivalent to 5.8 cm) than their non-carrier relatives 
3
. Heterozygous mutations in genes associated with 15 
bone growth regulation similarly impacted height: in a large family with many individuals heterozygous for 16 
a NPR2 mutation, carriers were 1.4 SDS shorter than non-carriers (equivalent to 9.1 cm) 2. In all of these 17 
studies, the clinical presentation of heterozygous individuals was much milder than the disorder seen in 18 
patients homozygous for the same mutations. Altogether, the presence of these rare pathogenic mutations in 19 
heterozygous state suggests that loss of one functional allele may result in low-normal height and borderline 20 
short stature. 21 
Finally, we observed that individuals with heterozygous STAT5B c.424_427del mutation reported 22 
more dermopathies and skin allergies when compared to their non-carrier relatives (p = 0.004). There was no 23 
difference in pneumopathies or other allergies reported by both groups, although two heterozygous carriers 24 
(a cousin of the probands and her father) had severe pneumopathy of unknown etiology. Further 25 
investigations are necessary to better characterize the potential effects of heterozygous STAT5B mutations in 26 
immunologic alterations. 27 
In conclusion, we demonstrated that STAT5B mutations in heterozygous state exert a significant 28 
negative impact on height. This effect is milder than the effect seen in homozygous state, with height usually 29 
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within the low normal range. Our results support the hypothesis that heterozygosity of rare pathogenic 1 
variants contributes to normal height heritability. Whether the cumulative effect of such variants could be 2 
responsible for a proportion of the missing height heritability posed by GWAS studies remains to be 3 
determined. 4 
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 1 
Figure legends:  2 
 3 
Figure 1: Comparison of height SDS distribution among adult heterozygous carriers of STAT5B 4 
c.424_427del mutation (n = 25), their non-carrier relatives (n = 28) and a population sample from the same 5 
region in the south of Brazil (n=1,099). 6 
 7 
Supplemental figure 1: The largest Brazilian family with STAT5B c.424_427del mutation. Subjects 8 
homozygous for STAT5B c.424_427del mutation are indicated by black symbols; heterozygous carriers by 9 
gray symbols and non-carriers by white symbols. The symbol * refers to two individuals with severe 10 
pneumopathy of unknown etiology. 11 
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Table 1: Clinical and biochemical characteristics of heterozygous carriers of STAT5B 
c.424_427del mutation vs. non-carriers 
 WT/Mut WT/WT p 
n 32 38  
Dermopathy 9:32 1:38 0.004 
Severe pneumopathy 1:32 0:38 n.s. 
Height SDS -0.8 ± 0.9* -0.2 ± 1.0 0.009 
Basal GH (ng/mL) 1.4 ± 2.2 1.0 ± 1.6 n.s. 
IGF-1 SDS -0.4 ± 1.2  0.3 ± 1.2 0.028 
IGFBP-3 SDS -0.9 ± 1.4 0.0 ± 1.5 0.02 
Prolactin (ng/mL) 12.5 ± 7.2 13.0 ± 10.6 n.s. 
Glucose (mg/dL) 90 ± 14 83 ± 13 n.s. 
Insulin (µUI/mL) 6.9 ± 7.3 6.4 ± 3.9 n.s. 
Hemoglobin (g/dL) 13.3 ± 1.3 13.4 ± 1.5 n.s. 
Leucocytes (cells/mm3) 6893 ± 2008 6935 ± 2695 n.s. 
Lymphocytes (cells/mm
3
) 3998 ± 1292 3598 ± 1329 n.s. 
IgG (mg/dL) 1022 ± 205 1054 ± 249 n.s. 
IgA (mg/dL) 244 ± 141 225 ± 123 n.s. 
IgE (UI/mL) 220 ± 325 143 ± 191 n.s. 
SDS – standard deviation score; GH – growth hormone; IGF-1 – insulin-like growth factor 1; IGFBP-3 
– insulin-like growth factor binding protein 3; IgG/IgA/IgE – immunoglobulins G, A and E; n.s. – non-
significant. 
* - excluding one heterozygous carrier with severe short stature (height SDS -3.5) 
Values are expressed as mean ± SD 
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Table 2: Data of index patients homozygous for STAT5B mutations and their first-degree relatives. 
Family n
o
 Ref Consanguinity cDNA mutation Origin  Local height SDS 
 Patient  Fathers Mothers Siblings 
1 9 Yes c.1888G>C Argentina  -7.5  -0.3 -1.2  
2 10 Yes c.1191insG Turkey  -7.8  -0.9 -0.6  
3 11 No c.1102insC Caribbean  -5.9  -2.8 -0.8 -2.3 / -0.8 
4 12 No c.454C>T Argentina  -9.9  -2.2 -3.3 -2.0 
5 13 Yes c.1680delG Kuwait  -5.6 / -5.8  -1.3 -0.6  
6 14 Adopted c.454C>T Argentina  -5.3  NA NA  
7 15 No c.424_427del Brazil  -5.6 / -3.0  -1.5 -1.0  
8 16 Adopted c.1937T>C Argentina  -5.95  NA NA  
9 19 Yes c.424_427del Brazil  NA*  -0.9 -1.9  
Mean ± SDS   -6.2 ± 1.8  -1.4 ± 0.8 
-1.2 (-3.3; -0.3) Median (range)   -5.9 (-9.9; -3.0)  
NA: not available 
* - patients died before anthropometric assessment. 
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